Nielsen and Ainsworth (Aug. 22 issue) 1 state that etanercept is not effective in the treatment
of inflammatory bowel disease because it may lack the capacity to induce mucosal T-cell …

Despite all of the advances in our understanding of the pathophysiology of inflammatory
bowel disease (IBD), we still do not know its cause. Some of the most recently available data …

Tumor necrosis factor (TNF) antagonists are the cornerstone of therapy for moderately to
severely active inflammatory bowel disease (IBD). Although our understanding of …

BACKGROUND INFLAMMATORY BOWEL DISEASE Crohn's disease and ulcerative colitis
are idiopathic, chronic inflammatory bowel diseases (IBD) empirically defined by clinical …

Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab
pegol and golimumab, have been proven to be effective for the treatment of patients with …

Background Anti‐tumour necrosis factor‐α (TNF α) antibodies are efficacious in
inflammatory bowel disease (IBD). These drugs carry the theoretical risk of malignancy …

Antitumor necrosis factor α (anti-TNF) agents have dramatically influenced management of
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …

Introduction During the last decades, biologics have revolutionized the treatment of Crohn's
disease and ulcerative colitis. Even though the inflammatory bowel disease (IBD) …

Although antagonists of tumor necrosis factor have resulted in major therapeutic benefits in
inflammatory bowel disease, the magnitude and durability of response are variable. Similar …

Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in
inflammatory bowel disease management. Nevertheless, further knowledge and therapeutic …